Brief: Mabpharm Announces Approval Of Clinical Trial Application Of Biological Class I New Drug Cmab017
05/07/2022 14:53
July 5 (Reuters) - Mabpharm Ltd 2181.HK :
* APPROVAL OF CLINICAL TRIAL APPLICATION OF BIOLOGICAL CLASS
I NEW
DRUG CMAB017 BY NMPA OF CHINA
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008